HDACi Carrier for Dry Eye Disease via IL-17 Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease (DED) primarily address symptoms rather than the underlying cause, leading to transient relief and potential side effects such as steroid-induced glaucoma and retinopathy, while also not addressing the imbalance between pro-inflammatory and immunosuppressive cells.
Innovation Solution
Administration of a therapeutic agent-loaded carrier containing a histone deactylase inhibitor (HDACi) to the ocular site, which promotes the local induction of regulatory T cells (Tregs) to restore immunological homeostasis and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used to treat DED, then ocular inflammation is suppressed and symptoms are alleviated, but severe side effects such as steroid-induced glaucoma and retinopathy occur with long-term use
Solution Approach 1:
The patent uses small interfering RNA (siRNA) as an intermediary to specifically target and silence the gene encoding interleukin-17 (IL-17), a key pro-inflammatory cytokine. This molecular intermediary approach provides targeted anti-inflammatory action without the broad immunosuppression caused by corticosteroids, thereby avoiding steroid-induced side effects while maintaining effective inflammation control
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific protein inhibition (corticosteroids) to specific gene silencing (siRNA). By targeting the IL-17 gene at the molecular level, the treatment achieves precise modulation of the inflammatory pathway, reducing inflammation effectively while minimizing off-target effects and systemic side effects associated with traditional corticosteroid therapy
2Ease of operation
If artificial tear substitutes are used to provide temporary relief, then symptoms are alleviated, but preservatives such as benzalkonium chloride cause tear film hyperosmolarity and eye irritation
Solution Approach 1:
The patent extracts and eliminates the harmful preservative components (such as benzalkonium chloride) from the tear substitute formulation. By removing these irritant substances while retaining the therapeutic benefits of tear supplementation, the treatment provides symptom relief without causing tear film hyperosmolarity or additional eye irritation
Solution Approach 2:
The patent employs preservative-free, single-use artificial tear formulations that are discarded after one use. This disposable approach eliminates the need for long-term preservatives in multi-dose bottles, preventing cumulative preservative exposure and associated side effects while maintaining effective symptom relief
3Duration of action of stationary object
If punctal plugs are inserted to reduce tear turnover, then tear retention is improved, but plug retention issues and increased risk of ocular infections occur
Solution Approach 1:
The patent replaces the mechanical punctal plug system with a molecular therapy approach using siRNA. Instead of physically occluding the punctum with a foreign body that carries retention and infection risks, the treatment delivers nucleic acid molecules that specifically suppress IL-17 production, addressing the underlying inflammation without mechanical intervention and its associated complications
4Ease of operation
If palliative treatments are used to address symptoms, then temporary relief is provided, but the underlying cause of DED involving pro-inflammatory immune cells is not addressed
Solution Approach 1:
The patent takes preliminary action by targeting the root cause of DED (IL-17-mediated inflammation) before symptoms fully develop or worsen. By silencing the IL-17 gene proactively, the treatment prevents the inflammatory cascade that leads to symptomatology, rather than merely treating symptoms after they occur. This upstream intervention addresses both the underlying cause and prevents symptom recurrence
Solution Approach 2:
The patent introduces siRNA as a molecular intermediary that specifically targets and silences the IL-17 gene, thereby blocking the pro-inflammatory signaling pathway at its source. This targeted molecular approach addresses the underlying immunological dysfunction involving pro-inflammatory immune cells, rather than merely suppressing symptoms with broad-acting palliative treatments
Data Source
AI summary
A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent is a histone deactylase inhibitor.